133 related articles for article (PubMed ID: 11181123)
1. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
Paya CV
Clin Infect Dis; 2001 Feb; 32(4):596-603. PubMed ID: 11181123
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus: pathogen, paradigm, and puzzle.
Boeckh M; Geballe AP
J Clin Invest; 2011 May; 121(5):1673-80. PubMed ID: 21659716
[TBL] [Abstract][Full Text] [Related]
3. Association between cytomegalovirus infection and neurological disorders: A systematic review.
Sanami S; Shamsabadi S; Dayhimi A; Pirhayati M; Ahmad S; Pirhayati A; Ajami M; Hemati S; Shirvani M; Alagha A; Abbarin D; Alizadeh A; Pazoki-Toroudi H
Rev Med Virol; 2024 May; 34(3):e2532. PubMed ID: 38549138
[TBL] [Abstract][Full Text] [Related]
4. How low should we go? Potential and challenges of ultrasensitive CMV assays and solid organ transplantation.
Kotton CN
Transpl Infect Dis; 2024 Feb; 26(1):e14239. PubMed ID: 38269440
[No Abstract] [Full Text] [Related]
5. Cytomegalovirus infection after renal transplantation.
Al Atbee MYN; Tuama HS
J Med Life; 2022 Jan; 15(1):71-77. PubMed ID: 35186139
[TBL] [Abstract][Full Text] [Related]
6. Impact of cytomegalovirus infection on biliary disease after liver transplantation - maybe an essential factor.
Liu JY; Zhang JR; Sun LY; Zhu ZJ; Wei L; Qu W; Zeng ZG; Liu Y; Zhao XY
World J Clin Cases; 2021 Dec; 9(35):10792-10804. PubMed ID: 35047591
[TBL] [Abstract][Full Text] [Related]
7. Plasma cytomegalovirus DNA load predicts outcomes in liver transplant recipients.
Hung HC; Hsu PJ; Lee JC; Wang YC; Cheng CH; Wu TH; Wu TJ; Chou HS; Chan KM; Lee WC; Lee CF
Immun Inflamm Dis; 2021 Mar; 9(1):134-143. PubMed ID: 33145985
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir-Resistant CMV Colitis in a Donor-Seronegative/Recipient-Seronegative Liver Transplant Patient.
Igbinedion SO; Patel K; Samant H; Wellman GP
ACG Case Rep J; 2018; 5():e102. PubMed ID: 30643845
[TBL] [Abstract][Full Text] [Related]
9. Cyclophilin A as a target in the treatment of cytomegalovirus infections.
A Abdullah A; Abdullah R; A Nazariah Z; N Balakrishnan K; Firdaus J Abdullah F; A Bala J; Mohd-Lila MA
Antivir Chem Chemother; 2018; 26():2040206618811413. PubMed ID: 30449131
[TBL] [Abstract][Full Text] [Related]
10. Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.
Loechelt BJ; Green M; Gottlieb PA; Blumberg E; Weinberg A; Quinlan S; Baden LR;
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):198-204. PubMed ID: 26336066
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives.
Requião-Moura LR; deMatos AC; Pacheco-Silva A
Einstein (Sao Paulo); 2015; 13(1):142-8. PubMed ID: 25993081
[TBL] [Abstract][Full Text] [Related]
12. Comparison of quantitation of cytomegalovirus DNA by real-time PCR in whole blood with the cytomegalovirus antigenemia assay.
Kwon S; Jung BK; Ko SY; Lee CK; Cho Y
Ann Lab Med; 2015 Jan; 35(1):99-104. PubMed ID: 25553288
[TBL] [Abstract][Full Text] [Related]
13. Controlling cytomegalovirus: helping the immune system take the lead.
Hanley PJ; Bollard CM
Viruses; 2014 May; 6(6):2242-58. PubMed ID: 24872114
[TBL] [Abstract][Full Text] [Related]
14. Viral infection in renal transplant recipients.
Cukuranovic J; Ugrenovic S; Jovanovic I; Visnjic M; Stefanovic V
ScientificWorldJournal; 2012; 2012():820621. PubMed ID: 22654630
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection.
Abate D; Fiscon M; Saldan A; Cofano S; Mengoli C; Sgarabotto D; d'Agostino C; Barzon L; Cusinato R; Toscano G; Feltrin G; Gambino A; Gerosa G; Palù G
J Clin Microbiol; 2012 Jun; 50(6):1974-80. PubMed ID: 22461674
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
Park SY; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
J Clin Microbiol; 2011 Dec; 49(12):4179-84. PubMed ID: 22031700
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Real-time PCR to ELISA for the detection of human cytomegalovirus infection in renal transplant patients in the Sudan.
Enan KA; Rennert H; El-Eragi AM; El Hussein AR; Elkhidir IM
Virol J; 2011 May; 8():222. PubMed ID: 21569506
[TBL] [Abstract][Full Text] [Related]
18. Increased morbidity and mortality in murine cytomegalovirus-infected mice following allogeneic bone marrow transplant is associated with reduced surface decay accelerating factor expression.
El-Amouri IS; Bani-Ahmad M; Tang-Feldman Y; Lin F; Ko C; Pomeroy C; Oakley OR
Clin Exp Immunol; 2010 Nov; 162(2):379-91. PubMed ID: 20840652
[TBL] [Abstract][Full Text] [Related]
19. Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells.
Yu Y; Pilgrim P; Yan J; Zhou W; Jenkins M; Gagliano N; Bumm K; Cannon M; Milzani A; Dalle-Donne I; Kast WM; Cobos E; Chiriva-Internati M
J Transl Med; 2008 Oct; 6():56. PubMed ID: 18834548
[TBL] [Abstract][Full Text] [Related]
20. The history of cytomegalovirus and its diseases.
Ho M
Med Microbiol Immunol; 2008 Jun; 197(2):65-73. PubMed ID: 18087722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
